


ABION and Deep Bio Sign MOU to Advance AI-Driven Companion Diagnostics and Clinical Trials

SEOUL, SOUTH KOREA, September 5, 2024 /EINPresswire.com/ -- ABION today announced the signing of a Memorandum of Understanding (MOU) with Deep Bio, a pioneering leader in AI-powered digital pathology. This strategic collaboration is designed to leverage cutting-edge AI technologies to enhance cancer diagnostics, optimize the development of cancer therapeutics, and accelerate clinical trials.



Under the terms of the agreement, ABION will integrate Deep Bio's advanced AI-driven c-MET immunohistochemistry (IHC) interpretation services into its clinical development programs. This includes the application of AI technology to ABION's key pipeline assets, ABN401 (vabametakib) and ABN101, to bolster the precision of in vitro diagnostic (IVD) and companion diagnostic (CDx) services. The collaboration aims to expedite clinical trials by improving patient recruitment and identification, particularly within the scope of ABION's ongoing combination trials involving vabametakib and lazertinib.

Commenting on the partnership, June Yeong Choi, Vice President of ABION stated, "Incorporating Deep Bio's AI-powered IHC interpretation technology into our lung cancer therapeutic, vabametakib, marks a significant step forward in enhancing our clinical trial capabilities. This collaboration is expected to increase the competitiveness of our drug pipeline by enabling more precise and efficient patient stratification."

Sun Woo Kim, CEO of Deep Bio, added, "A critical challenge in clinical trials is the accurate identification of patient populations most likely to benefit from emerging therapies. Our DeepCDx solution is designed to address this challenge, thereby streamlining the clinical trial process and supporting ABION's pursuit of breakthrough cancer treatments."

ABION is progressing with combination trials of vabametakib and lazertinib, with initial patient recruitment anticipated later this year. The recent FDA approval of the lazertinib and

amivantamab combination therapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations are expected to positively influence these trials, serving as a significant validation of ABION's therapeutic strategy.

To further extend its leadership in oncology, ABION is committed to expanding the application of AI technologies across various therapeutic areas through its ongoing collaboration with Deep Bio. By leveraging AI-powered companion diagnostics, this strategic initiative will support the acceleration of clinical trials across multiple indications.

Meanwhile, Deep Bio continues to set industry standards as a top-tier AI company in digital pathology, renowned for its groundbreaking AI-based prostate cancer diagnostic software, DeepDx Prostate, which has received CE-IVD certification in Europe. Leveraging its advanced AI capabilities, Deep Bio is expanding its focus to include the development of companion diagnostics, offering tailored solutions that enable biopharma companies to enhance the precision and impact of their drug development pipelines.

About Deep Bio

Founded in 2015, Deep Bio Inc. develops AI-powered solutions for cancer pathology diagnostics, utilizing advanced deep learning technologies to enhance diagnostic precision and pathologist efficiency. The company specializes in in-vitro diagnostic medical device software (IVD SaMD) that integrates data-driven insights to support clinical decision-making.

Deep Bio's flagship AI solution, DeepDx Prostate, marked with European CE-IVD, processes Whole Slide Images (WSI) to identify and segment cancerous lesions accurately. The software provides comprehensive classification by Gleason pattern, precise tumor localization, and critical metrics such as Gleason score quantification and tumor volume assessment, which are essential for diagnosis, prognosis, and treatment planning.

This AI technology enables detailed analysis and reporting, supporting healthcare professionals with precise diagnostic insights. Recognized for its innovation with the CES Innovation Award in 2024, Deep Bio is dedicated to advancing pathology workflows and improving patient outcomes globally.

Diane Kim
Deep Bio
+82 10-2938-6161
diane.kim@deepbio.co.kr

This press release can be viewed online at: <https://www.einpresswire.com/article/739408762>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.